Whittier Trust’s Cymabay Therapeutics CBAY Stock Holding History

Whittier Trust’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-851	Closed	-$4K	–	1632
2019 Q3	$4K	Buy	+851	New	+$5.15K	﹤0.01%	1304

Other funds holding CBAY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Whittier Trust's CBAY Position: Q4 2019 in Review

Whittier Trust sold out of Cymabay Therapeutics (CBAY) in Q4 2019, closing a stake of 851 shares — an estimated $4K sold.

Whittier Trust first reported a position in CBAY in Q3 2019 and held it in 1 quarter. The position peaked at $4K in Q3 2019. 113 funds tracked by Wall St. Rank hold CBAY as of Q4 2019.

Whittier Trust reported no remaining Cymabay Therapeutics position as of Q4 2019 after selling out during the quarter.
Whittier Trust sold 851 Cymabay Therapeutics shares in Q4 2019, an estimated $4K.
Whittier Trust first reported a position in Cymabay Therapeutics in Q3 2019 and held it in 1 quarter.
Whittier Trust's Cymabay Therapeutics position peaked at $4K in Q3 2019.
113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2019.

Based on Whittier Trust's 13F filing for Q4 2019, filed 31 Jan 2020.